Ibio, Inc.

Ibio, Inc. company information, Employees & Contact Information

Explore related pages

Related company profiles:

iBio is a cutting-edge biotech company leveraging AI and advanced computational biology to develop next-generation biopharmaceuticals for cardiometabolic diseases, obesity, cancer and other hard-to-treat diseases. By combining proprietary 3D modeling with innovative drug discovery platforms, iBio is creating a pipeline of breakthrough antibody treatments to address significant unmet medical needs. Our mission is to transform drug discovery, accelerate development timelines, and unlock new possibilities in precision medicine. For more information, visit www.ibioinc.com

Company Details

Employees
56
Founded
-
Address
11750 Sorrento Valley Road,
Phone
302-355-0650
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
San Diego, CA
Looking for a particular Ibio, Inc. employee's phone or email?

Ibio, Inc. Questions

News

iBio to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference - Sahm

iBio to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference Sahm

iBio Reports Fiscal Third Quarter 2025 Financial Results - Yahoo Finance

iBio Reports Fiscal Third Quarter 2025 Financial Results Yahoo Finance

iBio Reveals 3 Breakthrough Obesity Drug Candidates: AI-Powered Antibody Pipeline Shows Promise - Stock Titan

iBio Reveals 3 Breakthrough Obesity Drug Candidates: AI-Powered Antibody Pipeline Shows Promise Stock Titan

iBio to Present New Preclinical Data on Its Activin E Antibody at Two Upcoming Scientific Conferences, ObesityWeek® and PEGS Europe 2025 - The Manila Times

iBio to Present New Preclinical Data on Its Activin E Antibody at Two Upcoming Scientific Conferences, ObesityWeek® and PEGS Europe 2025 The Manila Times

iBio Presents Next-Generation Obesity and Cardiometabolic Pipeline Candidates on June 24 Conference Call - Yahoo Finance

iBio Presents Next-Generation Obesity and Cardiometabolic Pipeline Candidates on June 24 Conference Call Yahoo Finance

iBio Reports Fiscal Year 2025 Financial Results and Provides Corporate Update - Yahoo Finance

iBio Reports Fiscal Year 2025 Financial Results and Provides Corporate Update Yahoo Finance

iBio Announces New Investments from Board Members and Officers - Yahoo Finance

iBio Announces New Investments from Board Members and Officers Yahoo Finance

iBio Expands Cardiometabolic and Obesity Program with - GlobeNewswire

iBio Expands Cardiometabolic and Obesity Program with GlobeNewswire

iBio and AstralBio Unveil Obesity Program with Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results - Yahoo Finance

iBio and AstralBio Unveil Obesity Program with Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results Yahoo Finance

iBio to Begin Trading on the Nasdaq Stock Exchange - GlobeNewswire

iBio to Begin Trading on the Nasdaq Stock Exchange GlobeNewswire

iBio Announces Proposed Public Offering - GlobeNewswire

iBio Announces Proposed Public Offering GlobeNewswire

iBio Announces Closing of $50 Million Public Offering - GlobeNewswire

iBio Announces Closing of $50 Million Public Offering GlobeNewswire

iBio Announces Pricing of $50 Million Public Offering - GlobeNewswire

iBio Announces Pricing of $50 Million Public Offering GlobeNewswire

iBio (NASDAQ: IBIO) fireside chat Nov 10 at 8:30 a.m. ET on obesity pipeline, Guggenheim - Stock Titan

iBio (NASDAQ: IBIO) fireside chat Nov 10 at 8:30 a.m. ET on obesity pipeline, Guggenheim Stock Titan

iBio (NASDAQ: IBIO) to share new IBIO-610 preclinical data at ObesityWeek and PEGS Europe - Stock Titan

iBio (NASDAQ: IBIO) to share new IBIO-610 preclinical data at ObesityWeek and PEGS Europe Stock Titan

iBio, Inc. Announces Pricing of $4.5 Million Public Offering - Yahoo Finance

iBio, Inc. Announces Pricing of $4.5 Million Public Offering Yahoo Finance

iBio Announces Sale of Preclinical PD-1 Agonist Antibody Program to Otsuka - Yahoo Finance

iBio Announces Sale of Preclinical PD-1 Agonist Antibody Program to Otsuka Yahoo Finance

Breakthrough Obesity Treatment: iBio's AI-Powered Amylin Antibody Matches Leading Drug Efficacy - Stock Titan

Breakthrough Obesity Treatment: iBio's AI-Powered Amylin Antibody Matches Leading Drug Efficacy Stock Titan

iBio Raises $6.2 Million Through Warrant Inducement Transaction - GlobeNewswire

iBio Raises $6.2 Million Through Warrant Inducement Transaction GlobeNewswire

iBio Initiates Non-Human Primate Study of First-in-Class - GlobeNewswire

iBio Initiates Non-Human Primate Study of First-in-Class GlobeNewswire

iBio Expands Cardiometabolic and Obesity Pipeline through - GlobeNewswire

iBio Expands Cardiometabolic and Obesity Pipeline through GlobeNewswire

iBio Closes Sale of Manufacturing Facility in Texas - GlobeNewswire

iBio Closes Sale of Manufacturing Facility in Texas GlobeNewswire

iBio’s First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model - GlobeNewswire

iBio’s First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model GlobeNewswire

iBio Announces Reverse Stock Split - GlobeNewswire

iBio Announces Reverse Stock Split GlobeNewswire

iBio Appoints Dr. Martin Brenner as CEO, Felipe Duran as CFO to Oversee Company’s Next Stage of Growth - Yahoo Finance

iBio Appoints Dr. Martin Brenner as CEO, Felipe Duran as CFO to Oversee Company’s Next Stage of Growth Yahoo Finance

iBio CEO Thomas Isett Resigns - citybiz

iBio CEO Thomas Isett Resigns citybiz

iBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases - Stock Titan

iBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases Stock Titan

iBio Further Expands Tech Stack with ShieldTx™; Enhances Immuno-Oncology Development Pipeline with Conditionally Activated MUC16xCD3 Bispecific - Stock Titan

iBio Further Expands Tech Stack with ShieldTx™; Enhances Immuno-Oncology Development Pipeline with Conditionally Activated MUC16xCD3 Bispecific Stock Titan

iBio Announces CEO Departure - Yahoo Finance

iBio Announces CEO Departure Yahoo Finance

iBio Reports Fiscal Third Quarter 2022 Financial Results and Provides Corporate Update - Yahoo Finance

iBio Reports Fiscal Third Quarter 2022 Financial Results and Provides Corporate Update Yahoo Finance

iBio Announces Sale of Preclinical PD-1 Agonist Antibody Program to Otsuka - citybiz

iBio Announces Sale of Preclinical PD-1 Agonist Antibody Program to Otsuka citybiz

iBio Announces Pricing of $3.5 Million Underwritten Public Offering - Stock Titan

iBio Announces Pricing of $3.5 Million Underwritten Public Offering Stock Titan

iBio Reports Preliminary Unaudited Fiscal Year 2022 Financial Results and Provides Corporate Update - GlobeNewswire

iBio Reports Preliminary Unaudited Fiscal Year 2022 Financial Results and Provides Corporate Update GlobeNewswire

iBio Acquires RubrYc Therapeutics’ AI Drug Discovery Platform and Pipeline - GlobeNewswire

iBio Acquires RubrYc Therapeutics’ AI Drug Discovery Platform and Pipeline GlobeNewswire

iBio Establishes Oncology Drug Discovery Pipeline with Three New Antibody Programs - GlobeNewswire

iBio Establishes Oncology Drug Discovery Pipeline with Three New Antibody Programs GlobeNewswire

Top Ibio, Inc. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant